for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). “This most recent meeting with PMDA had several important outcomes,” said Peter Altman, Ph.D., BioCardia’s President ...
We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.
We screened 355 patients and recruited 253 patients. We excluded seven patients upon further review of case notes who did not have a clinical diagnosis of ischaemic stroke when final follow-up ...